{"id":34444,"date":"2025-12-08T09:51:00","date_gmt":"2025-12-08T14:51:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=34444"},"modified":"2025-12-08T11:42:05","modified_gmt":"2025-12-08T16:42:05","slug":"the-patent-cliff-playbook-a-strategic-guide-for-hospital-formulary-management-and-budget-forecasting","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-patent-cliff-playbook-a-strategic-guide-for-hospital-formulary-management-and-budget-forecasting\/","title":{"rendered":"The Patent Cliff Playbook: A Strategic Guide for Hospital Formulary Management and Budget Forecasting"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Introduction: The Strategic Imperative of the Patent Cliff for Health Systems<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image alignright size-medium\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"164\" src=\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2025\/12\/unnamed-19-300x164.jpg\" alt=\"\" class=\"wp-image-35739\" srcset=\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2025\/12\/unnamed-19-300x164.jpg 300w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2025\/12\/unnamed-19-768x419.jpg 768w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2025\/12\/unnamed-19.jpg 1024w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The term &#8220;patent cliff&#8221; signifies a period of immense financial peril, where blockbuster drugs lose their market exclusivity, leading to precipitous revenue declines for innovator companies.<sup>1<\/sup> For the nation&#8217;s hospitals and health systems, however, this cliff is not a threat but the single largest, most predictable cost-saving opportunity hiding in plain sight. An impending wave of patent expirations is set to release over $200 billion in branded drug sales into the competitive sphere by 2030, with an estimated $356 billion at risk between 2023 and 2028 alone.<sup>3<\/sup> This seismic shift in market value represents a critical chance for health systems to achieve massive budget relief.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This report puts forth a new paradigm for hospital pharmacy management. It advocates for a move away from the pharmacy&#8217;s traditional role as a reactive cost center, perpetually grappling with escalating drug expenditures that strain hospital budgets.<sup>5<\/sup> Instead, by adopting a strategic, intelligence-driven approach to patent expirations, the hospital pharmacy can be transformed into a proactive value engine\u2014a strategic driver of financial sustainability for the entire organization. This requires a fundamental shift from the conventional, calendar-based formulary review process to a forward-looking model that anticipates and capitalizes on market changes.<sup>7<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This playbook is designed for the key decision-makers within a health system: Directors of Pharmacy, Chief Financial Officers, and the members of the Pharmacy and Therapeutics (P&amp;T) Committee. It provides a detailed, step-by-step guide to building a competitive intelligence function within the pharmacy, forecasting the financial impact of generic and biosimilar entry with unprecedented precision, and operationalizing these insights to maximize savings while upholding the highest standards of patient care and safety.<sup>8<\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Section 1: Understanding the Exclusivity Landscape: The Rules of the Game<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">To effectively capitalize on the patent cliff, hospital leaders must first develop a nuanced understanding of the legal and regulatory frameworks that govern a drug&#8217;s market exclusivity. This landscape is far more complex than a single patent expiration date, involving an overlapping web of intellectual property and regulatory protections.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1.1 Beyond the 20-Year Myth: The &#8220;Exclusivity Stack&#8221; Explained<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A common and costly misconception is that a drug&#8217;s market monopoly lasts for 20 years from its launch. In reality, the 20-year patent term begins from the date the patent application is <em>filed<\/em>, not when the drug is approved by the Food and Drug Administration (FDA).<sup>11<\/sup> Given that the research, development, and regulatory review process can consume 10 to 15 years, the &#8220;effective patent life&#8221;\u2014the actual period of market exclusivity\u2014is often much shorter, averaging just 7 to 12 years.<sup>11<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A drug&#8217;s protection is not a single wall but a fortress built of multiple, overlapping defenses, a concept best described as the &#8220;Exclusivity Stack&#8221;.<sup>7<\/sup> To accurately predict the true date of generic entry, one must analyze this entire stack, which includes various patent types and non-patent regulatory exclusivities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The key patent types for formulary managers to track include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Composition of Matter Patents:<\/strong> Considered the &#8220;crown jewel&#8221; of pharmaceutical intellectual property, this patent protects the active pharmaceutical ingredient (API)\u2014the core molecule itself.<sup>7<\/sup><\/li>\n\n\n\n<li><strong>Formulation and Delivery Method Patents:<\/strong> These secondary patents protect novel delivery mechanisms, such as an extended-release tablet, a transdermal patch, an inhaler device, or a specific nanoparticle-based formulation.<sup>3<\/sup><\/li>\n\n\n\n<li><strong>Method of Use Patents:<\/strong> These patents cover new therapeutic uses or indications for a drug that may be discovered long after its initial approval.<sup>11<\/sup><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The strategic layering of these secondary patents is a primary &#8220;evergreening&#8221; tactic used by brand manufacturers to prolong their monopoly well beyond the expiration of the core composition of matter patent.<sup>11<\/sup> This creates a dense &#8220;patent thicket&#8221; that makes simplistic expiration date tracking dangerously misleading for budget forecasting.<sup>3<\/sup> For a hospital, relying solely on the primary patent&#8217;s expiration date for a high-spend drug can lead to a significant, unplanned negative budget variance. The forecasting process must assume that savings will materialize upon the primary patent&#8217;s expiration, but if a later-expiring formulation patent holds generic competition at bay for several more years, those budgeted savings will not be realized, creating a financial shortfall that must be covered by other departments.<sup>19<\/sup> Therefore, accurate financial planning requires a thorough mapping of the entire patent thicket to identify the true, last-to-expire patent.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1.2 Patents vs. Regulatory Exclusivities: A Critical Distinction<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Operating independently from patents, which are granted by the U.S. Patent and Trademark Office (USPTO), are regulatory exclusivities granted by the FDA. These two forms of protection are distinct and can run concurrently.<sup>21<\/sup> The earliest possible date for generic market entry is dictated by whichever barrier\u2014the last-to-expire relevant patent or the last-to-expire applicable exclusivity\u2014falls last.<sup>3<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key FDA regulatory exclusivities include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>New Chemical Entity (NCE) Exclusivity:<\/strong> A five-year period of data exclusivity granted for drugs containing an active ingredient never before approved by the FDA.<sup>11<\/sup><\/li>\n\n\n\n<li><strong>Orphan Drug Exclusivity (ODE):<\/strong> A seven-year period of market exclusivity for drugs developed to treat rare diseases (affecting fewer than 200,000 people in the U.S.).<sup>3<\/sup><\/li>\n\n\n\n<li><strong>New Clinical Investigation Exclusivity:<\/strong> A three-year exclusivity granted for new applications containing reports of new, essential clinical studies.<sup>3<\/sup><\/li>\n\n\n\n<li><strong>Pediatric Exclusivity:<\/strong> A six-month extension that is added to <em>all<\/em> other existing patent and exclusivity periods for a drug as a reward for conducting pediatric studies requested by the FDA.<sup>3<\/sup><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">While pediatric exclusivity is often viewed as a benign public health incentive, it functions as a powerful and frequently employed evergreening tool. For a blockbuster drug generating billions in annual revenue, this seemingly minor six-month delay in generic competition can cost the healthcare system hundreds of millions of dollars in unrealized savings.<sup>3<\/sup> For a hospital, the financial impact is direct and significant. If the pharmacy budgets for a generic version of a $10 million annual-spend drug to become available on January 1, a last-minute pediatric extension delaying the launch to July 1 creates an un-budgeted expense of approximately $5 million, as the hospital must continue purchasing the high-cost brand for an additional six months. Tracking potential pediatric exclusivity grants is therefore not an academic exercise but a critical component of financial risk management.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1.3 The Rules of Competition: Hatch-Waxman and the BPCIA<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The modern generic and biosimilar markets were fundamentally shaped by two pieces of landmark legislation: the Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act (for small-molecule drugs), and the Biologics Price Competition and Innovation Act of 2010 (BPCIA) (for biologics).<sup>11<\/sup> Hospital leaders should understand several key concepts from this legislation:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Abbreviated New Drug Application (ANDA):<\/strong> This streamlined pathway allows generic manufacturers to gain FDA approval by demonstrating their product is bioequivalent to the brand-name drug, without having to repeat costly and time-consuming clinical trials for safety and efficacy.<sup>13<\/sup><\/li>\n\n\n\n<li><strong>The &#8220;Paragraph IV&#8221; (PIV) Certification:<\/strong> This is the legal mechanism a generic company uses to challenge a brand&#8217;s listed patents, certifying to the FDA that the patents are invalid, unenforceable, or will not be infringed by the generic product. A PIV filing is the &#8220;starting gun&#8221; for patent litigation and the earliest reliable signal of impending generic competition.<sup>7<\/sup><\/li>\n\n\n\n<li><strong>180-Day Exclusivity:<\/strong> To incentivize these costly patent challenges, the Hatch-Waxman Act grants a 180-day period of marketing exclusivity to the <em>first<\/em> generic applicant to file a successful PIV certification. During this period, the FDA cannot approve any other generic versions of the drug, creating a lucrative duopoly between the brand and the first-generic filer.<sup>3<\/sup><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The 180-day exclusivity rule has a third-order implication that directly affects budget forecasting. During this six-month duopoly period, the first generic manufacturer typically launches at a relatively modest discount (e.g., 30-50% off the brand price) because it faces no other generic competition.<sup>23<\/sup> The dramatic price reductions of 80% or more that generate the largest savings for hospitals only occur<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>after<\/em> this exclusivity period expires and the market opens to multiple generic competitors.<sup>25<\/sup> A hospital budget that models an immediate 80% price drop upon the very first generic launch will overestimate savings for the first six months. A more sophisticated and accurate forecast must model a two-step price decline: a moderate drop during the 180-day exclusivity period, followed by a much steeper drop when full competition begins. This nuanced, two-stage model dramatically improves the accuracy of financial planning.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1.4 The Economics of Entry: Modeling Price Erosion<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The financial benefit of generic and biosimilar entry is not a binary event; it is a curve directly correlated with the number of market competitors. It is not enough to know <em>if<\/em> a generic is coming; the critical question for accurate forecasting is <strong><em>how many<\/em><\/strong> are coming. Synthesized data from the FDA and the Department of Health and Human Services (HHS) provides a clear model for this price erosion <sup>7<\/sup>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>With <strong>one<\/strong> generic competitor, the average price is 31-39% lower than the brand price.<\/li>\n\n\n\n<li>With <strong>two<\/strong> competitors, the average generic price is 44-54% lower.<\/li>\n\n\n\n<li>With <strong>four<\/strong> competitors, prices drop by 73-79%.<\/li>\n\n\n\n<li>With <strong>six or more<\/strong> competitors, prices can plummet by more than 95%.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This data underscores the strategic imperative for a hospital&#8217;s intelligence function to track <em>all<\/em> announced patent challengers for a given drug, not just the first filer. This information is the key to transforming a vague budget estimate into a data-driven financial projection.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>Table 1: The Exclusivity Stack: A Comparative Guide for Hospital Strategists<\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td><strong>Protection Type<\/strong><\/td><td><strong>Granting Body<\/strong><\/td><td><strong>Typical Duration<\/strong><\/td><td><strong>What It Protects<\/strong><\/td><td><strong>Key Strategic Implication for Hospitals<\/strong><\/td><\/tr><tr><td>Composition of Matter Patent<\/td><td>USPTO<\/td><td>20 years from filing<\/td><td>The core active pharmaceutical ingredient (API) molecule.<\/td><td>The foundational patent, but often not the last to expire.<\/td><\/tr><tr><td>Formulation\/Delivery Patent<\/td><td>USPTO<\/td><td>20 years from filing<\/td><td>A specific delivery method (e.g., extended-release, patch, inhaler).<\/td><td>A common &#8220;evergreening&#8221; tactic that can delay generic entry for years after the main patent expires. Must be tracked to avoid major forecasting errors.<\/td><\/tr><tr><td>Method of Use Patent<\/td><td>USPTO<\/td><td>20 years from filing<\/td><td>A new, FDA-approved therapeutic use for an existing drug.<\/td><td>Can block generic substitution for a specific indication even if the drug is generic for other uses, complicating formulary management.<\/td><\/tr><tr><td>New Chemical Entity (NCE) Exclusivity<\/td><td>FDA<\/td><td>5 years from approval<\/td><td>Data for a drug containing a never-before-approved active moiety.<\/td><td>A hard stop on generic entry. Generic application cannot even be filed until year 4 (NCE-1).<\/td><\/tr><tr><td>Orphan Drug Exclusivity (ODE)<\/td><td>FDA<\/td><td>7 years from approval<\/td><td>Market exclusivity for a drug treating a rare disease.<\/td><td>A powerful exclusivity that often runs concurrently with patents. The last-to-expire of ODE or patents determines biosimilar\/generic entry.<\/td><\/tr><tr><td>Pediatric Exclusivity (PED)<\/td><td>FDA<\/td><td>6 months<\/td><td>An extension added to all existing patents and exclusivities.<\/td><td>A frequently used tool that can add six months of monopoly pricing to a blockbuster drug, creating millions in un-budgeted hospital costs if not anticipated.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Sources: <sup>3<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>Table 2: Generic &amp; Biosimilar Price Erosion Model<\/td><td><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td><strong>Number of Market Competitors<\/strong><\/td><td><strong>Average Price Reduction (vs. Brand Price)<\/strong><\/td><td><strong>Data Source<\/strong><\/td><td><strong>Timeframe to Reach Reduction<\/strong><\/td><td><strong>Implication for Hospital Budget Forecast<\/strong><\/td><\/tr><tr><td>1<\/td><td>31-39%<\/td><td>FDA <sup>26<\/sup><\/td><td>Immediately upon entry<\/td><td>Forecast modest initial savings.<\/td><\/tr><tr><td>2<\/td><td>44-54%<\/td><td>FDA <sup>26<\/sup><\/td><td>Within first year<\/td><td>Savings accelerate but are not yet maximized.<\/td><\/tr><tr><td>3<\/td><td>~65%<\/td><td>Interpolated from FDA\/HHS data <sup>25<\/sup><\/td><td>1-2 years post-entry<\/td><td>Significant savings begin to materialize.<\/td><\/tr><tr><td>4<\/td><td>73-79%<\/td><td>FDA <sup>26<\/sup><\/td><td>1-3 years post-entry<\/td><td>Approaching maximum savings potential.<\/td><\/tr><tr><td>6+<\/td><td>&gt;95%<\/td><td>FDA <sup>26<\/sup><\/td><td>2-3+ years post-entry<\/td><td>Budget should reflect near-total price collapse.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Sources: <sup>7<\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Section 2: The Modern P&amp;T Committee: From Clinical Guardian to Financial Strategist<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Pharmacy &amp; Therapeutics (P&amp;T) Committee has long been the clinical backbone of the hospital formulary system. However, the crushing financial pressures of modern healthcare demand an evolution of this critical body from a purely clinical guardian to a savvy financial strategist.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2.1 The Evolving Role of the P&amp;T Committee in a Value-Based World<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Traditionally, the P&amp;T Committee\u2014a multidisciplinary group of physicians, pharmacists, nurses, and administrators\u2014has been responsible for managing the drug formulary to ensure the selection and use of the safest and most effective medications.<sup>8<\/sup> The primary decision-making criteria have historically been clinical efficacy and safety, with cost often considered only as a tie-breaker between two clinically equivalent agents.<sup>8<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In an era where drug costs are a leading driver of healthcare inflation and a direct threat to hospital financial viability, this traditional model is no longer sufficient.<sup>5<\/sup> The P&amp;T committee&#8217;s mandate must explicitly expand to embrace financial stewardship and strategic cost management as a co-equal priority alongside clinical excellence. This evolution is not about sacrificing quality for cost; it is about ensuring the long-term financial health of the institution so that it can continue to provide high-quality care to all patients.<sup>27<\/sup><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2.2 The Crushing Weight of Drug Costs on Hospital Operations<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The need for this evolution is not theoretical; it is a matter of institutional survival. Data reveals the staggering impact of pharmaceutical spending on hospitals. In New Jersey, for instance, total hospital drug spending more than doubled over a nine-year period, with drug expenses per adjusted admission soaring by 132%.<sup>5<\/sup> This relentless inflation forces hospitals into painful operational trade-offs, such as delaying critical infrastructure improvements, cutting staff, or reducing the scope of patient services\u2014all of which compromise the core mission of care delivery.<sup>5<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Furthermore, the impact of high drug costs and the frequent shortages they can engender extends beyond the direct budget line item. These events create significant operational drag and hidden labor costs. A single drug shortage can consume immense amounts of staff time as pharmacists and technicians scramble to source alternatives, physicians are contacted to approve changes to treatment plans, and pharmacy staff are diverted to perform emergency in-house compounding.<sup>5<\/sup> This diverts highly skilled, expensive clinical resources away from patient-facing activities like medication reconciliation, clinical interventions, and patient counseling. A proactive strategy that anticipates generic entry and manages inventory accordingly not only yields direct savings on the drug itself but also prevents these costly and disruptive operational fire drills, preserving precious clinical resources for their intended purpose.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2.3 Adapting the P&amp;T Process for the Patent Cliff<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A fundamental mismatch exists between the traditional P&amp;T review cycle and the event-driven nature of patent expirations. P&amp;T committees have historically delayed the review of new drugs for six to twelve months post-launch to allow for the accumulation of real-world clinical evidence.<sup>32<\/sup> Likewise, reviews of entire therapeutic classes are often conducted on a fixed, annual schedule.<sup>33<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This reactive, calendar-based workflow is fundamentally incompatible with the dynamic, intelligence-driven timeline of patent events. Waiting for a generic or biosimilar to appear on the market before initiating a formulary review means that the hospital is already behind. Maximum savings are realized only through swift and widespread adoption of the lower-cost alternative from day one.<sup>34<\/sup> This rapid uptake is impossible if the groundwork\u2014formulary approval, IT system updates, prescriber communication\u2014has not been completed<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>before<\/em> the launch. This reveals the need for a new, parallel workflow: a &#8220;Pre-Loss of Exclusivity&#8221; (Pre-LOE) review process. This process is not triggered by the calendar or a product launch, but by an intelligence signal, such as a PIV filing or a patent litigation settlement announcement, often 18-24 months in advance of the actual event.<sup>7<\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Section 3: The Proactive Formulary Playbook: An Integrated Workflow<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Implementing a proactive, intelligence-driven approach to formulary management requires a structured, step-by-step process. This section outlines a practical workflow that can be adapted by any hospital or health system.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3.1 Step 1: Building the Intelligence Engine<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The foundation of this strategy is a robust system for gathering and analyzing market intelligence.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Identify Key Data Sources:<\/strong> A hospital can begin by leveraging free, powerful public resources. The FDA&#8217;s <strong>Orange Book<\/strong> is the definitive source for patent and exclusivity data on small-molecule drugs.<sup>35<\/sup> The FDA&#8217;s<br><strong>Purple Book<\/strong> serves the same function for biological products, including biosimilars and interchangeable products.<sup>37<\/sup> For hospitals seeking greater efficiency and deeper analytics, commercial intelligence platforms like<br><strong>DrugPatentWatch<\/strong> offer significant value. These subscription services aggregate patent data, litigation updates, clinical trial information, and regulatory filings into a single, user-friendly dashboard, saving significant staff time and providing alerts on key events.<sup>7<\/sup><\/li>\n\n\n\n<li><strong>Form a Cross-Functional Team:<\/strong> This initiative cannot reside solely within the pharmacy. Success hinges on a collaborative team that includes expertise from the <strong>Pharmacy<\/strong> department (for clinical evaluation and therapeutic interchange assessment), the <strong>Finance<\/strong> department (for budget impact modeling and forecasting), and, where available, <strong>Legal or Compliance<\/strong> (for interpreting patent litigation news).<sup>7<\/sup><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3.2 Step 2: Mapping the Horizon (36-24 Months Pre-LOE)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The process begins with long-range planning focused on the highest-impact drugs.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Identify High-Impact Targets:<\/strong> The team should first generate a report of the top 50 to 100 highest-spend branded drugs within the health system. These are the medications where a generic or biosimilar switch will yield the most significant savings.<sup>34<\/sup><\/li>\n\n\n\n<li><strong>Build the &#8220;Exclusivity Map&#8221;:<\/strong> For each high-spend target, the team uses the intelligence sources to map out every listed patent and regulatory exclusivity. This involves identifying the expiration date of each protection and, most importantly, determining the &#8220;last-to-expire&#8221; barrier that represents the final hurdle to generic competition.<sup>7<\/sup> This exercise creates a preliminary, long-range forecast for potential generic entry and establishes a baseline timeline.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3.3 Step 3: Monitoring for the &#8220;First Signal&#8221; (24-18 Months Pre-LOE)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The timeline accelerates dramatically with the first sign of a direct patent challenge.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>The PIV Filing as a &#8220;Tripwire&#8221;:<\/strong> A Paragraph IV (PIV) certification filing by a generic manufacturer is the most critical early warning sign that a brand&#8217;s monopoly is being actively challenged.<sup>7<\/sup><\/li>\n\n\n\n<li><strong>Triggering the 30-Month Stay:<\/strong> Upon receiving notice of a PIV filing, the brand manufacturer typically files a patent infringement lawsuit within 45 days. This lawsuit automatically triggers a 30-month stay, during which the FDA cannot grant final approval to the generic application.<sup>14<\/sup> This event provides a more concrete, albeit still preliminary, window for a potential launch date. The hospital&#8217;s formal &#8220;Pre-LOE Review&#8221; process for that drug should be officially initiated at this point.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3.4 Step 4: From Courtroom to Formulary (18-6 Months Pre-LOE)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This phase involves translating legal events into firm financial and operational plans.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tracking Litigation and Settlements:<\/strong> The cross-functional team must monitor the progress of the patent litigation. Key court events, such as the <em>Markman<\/em> hearing where a judge construes the meaning of the patent&#8217;s claims, can provide strong signals about which party is likely to prevail.<sup>7<\/sup> However, the most valuable piece of intelligence is a settlement announcement.<\/li>\n\n\n\n<li><strong>The Power of a Settlement:<\/strong> The vast majority of pharmaceutical patent cases end in a settlement agreement, in which the brand and generic companies agree on a specific, contractually-binding date for the generic to launch.<sup>14<\/sup> This announcement is the &#8220;gold standard&#8221; of intelligence, as it transforms an uncertain forecast into a near-certainty. This date becomes the new anchor for all subsequent budget and operational planning.<\/li>\n\n\n\n<li><strong>Tracking All Challengers:<\/strong> Throughout this process, it is critical to continue monitoring for <em>all<\/em> PIV filers, not just the first one. As established in the price erosion model, the number of competitors is the primary determinant of how quickly and deeply prices will fall.<sup>7<\/sup><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3.5 Step 5: The Pre-LOE Formulary Review &amp; Operational Readiness (6-0 Months Pre-LOE)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">With a firm launch date identified, the focus shifts to execution.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>P&amp;T Committee Action:<\/strong> The P&amp;T committee conducts its formal Pre-LOE review. This involves evaluating the upcoming generic or biosimilar for addition to the formulary, assigning it to the most favorable tier (typically Tier 1 to encourage use), and approving any necessary updates to utilization management protocols, such as making the generic the preferred agent in a step-therapy pathway or establishing it as an automatic therapeutic interchange.<sup>8<\/sup><\/li>\n\n\n\n<li><strong>Operational Go-Live Plan:<\/strong> The pharmacy department executes a detailed pre-launch checklist to ensure a seamless transition on day one:<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Confirm that contract pricing for the new generic is loaded into the wholesaler&#8217;s system.<sup>34<\/sup><\/li>\n\n\n\n<li>Update all internal IT systems, including electronic health records (EHR), computerized physician order entry (CPOE) menus, and automated dispensing cabinets, to reflect the new generic&#8217;s preferred formulary status.<sup>44<\/sup><\/li>\n\n\n\n<li>Proactively communicate the upcoming switch to prescribers, nurses, and other clinical staff, providing education on the transition.<sup>9<\/sup><\/li>\n\n\n\n<li>Carefully manage inventory of the branded product, tapering down orders to minimize waste and avoid being stuck with expensive, soon-to-be-obsolete stock.<sup>39<\/sup><\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>Table 3: P&amp;T Committee Pre-LOE Action Checklist<\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td><strong>Timeframe<\/strong><\/td><td><strong>Key Intelligence Question<\/strong><\/td><td><strong>Action Item<\/strong><\/td><td><strong>Responsible Party<\/strong><\/td><\/tr><tr><td>36-24 Months Pre-LOE<\/td><td>What is the last-to-expire patent\/exclusivity for our top-spend drugs?<\/td><td>Identify top 50 brand drugs by spend. Build &#8220;Exclusivity Map&#8221; for each.<\/td><td>Pharmacy Analyst \/ Finance<\/td><\/tr><tr><td>24-18 Months Pre-LOE<\/td><td>Has a PIV challenge been filed?<\/td><td>Monitor FDA PIV list and intelligence platforms. Initiate 30-month stay countdown upon lawsuit filing.<\/td><td>Pharmacy Analyst<\/td><\/tr><tr><td>18-6 Months Pre-LOE<\/td><td>Has a settlement been reached? What is the launch date?<\/td><td>Track litigation status and settlement announcements. Update forecast with firm date.<\/td><td>Pharmacy Analyst \/ Legal<\/td><\/tr><tr><td>18-6 Months Pre-LOE<\/td><td>How many generic challengers have filed?<\/td><td>Monitor for additional PIV filers to inform price erosion model.<\/td><td>Pharmacy Analyst<\/td><\/tr><tr><td>6-3 Months Pre-LOE<\/td><td>Is the generic\/biosimilar approved for the formulary?<\/td><td>Conduct formal Pre-LOE review. Approve formulary addition and utilization management changes.<\/td><td>P&amp;T Committee<\/td><\/tr><tr><td>3-1 Months Pre-LOE<\/td><td>Are our IT systems and contracts ready for launch?<\/td><td>Confirm wholesaler contract loading. Update CPOE, EHR, and dispensing systems.<\/td><td>Pharmacy IT \/ Purchasing<\/td><\/tr><tr><td>1 Month Pre-LOE<\/td><td>Are prescribers and staff aware of the switch?<\/td><td>Disseminate communication and education materials to all relevant clinical staff.<\/td><td>Pharmacy Leadership \/ Clinical Specialists<\/td><\/tr><tr><td>Launch Day &amp; Post-Launch<\/td><td>How is the transition progressing?<\/td><td>Monitor uptake rates, track actual savings vs. forecast, and manage any patient\/provider issues.<\/td><td>Pharmacy Analyst \/ Clinical Pharmacists<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Sources: <sup>7<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>Table 4: Key Data Sources for Patent Expiration Monitoring<\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td><strong>Data Source<\/strong><\/td><td><strong>Cost<\/strong><\/td><td><strong>Key Information Provided<\/strong><\/td><td><strong>Use Case for Hospitals<\/strong><\/td><\/tr><tr><td>FDA Orange Book<\/td><td>Free<\/td><td>Lists all patents, regulatory exclusivities, and therapeutic equivalence evaluations for small-molecule drugs.<\/td><td>Foundational tool for building the initial &#8220;Exclusivity Map.&#8221;<\/td><\/tr><tr><td>FDA Purple Book<\/td><td>Free<\/td><td>Lists all licensed biological products, including reference products, biosimilars, and interchangeable products, along with exclusivity data.<\/td><td>Essential resource for tracking the biosimilar pipeline and exclusivity timelines.<\/td><\/tr><tr><td>FDA Paragraph IV Certifications List<\/td><td>Free<\/td><td>Lists drugs for which a PIV certification has been submitted.<\/td><td>The primary source for identifying the &#8220;first signal&#8221; of a patent challenge.<\/td><\/tr><tr><td>Commercial Intelligence Platforms (e.g., DrugPatentWatch)<\/td><td>Subscription<\/td><td>Aggregates patent, exclusivity, litigation, and clinical trial data into a single platform with alerts and analytics.<\/td><td>Provides efficiency, deeper insights, and real-time alerts on critical events like settlements, saving significant staff time.<\/td><\/tr><tr><td>U.S. Federal Court Dockets (PACER)<\/td><td>Per-page fee<\/td><td>Provides access to court filings for patent litigation cases.<\/td><td>Allows for in-depth tracking of litigation milestones for high-priority drugs.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Sources: <sup>7<\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Section 4: Advanced Applications: Navigating Biosimilars and Future Frontiers<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Beyond small-molecule generics, the principles of proactive patent management can be applied to the growing market for biosimilars and adapted for the future of pharmacy financial planning.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>4.1 The Biosimilar Challenge: A Unique Inpatient Opportunity<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">While the strategic framework for tracking patent cliffs is similar for biologics, biosimilars present a unique set of challenges and a particularly compelling opportunity for hospitals.<sup>22<\/sup> Biologics are large, complex molecules produced in living systems, meaning a biosimilar is &#8220;highly similar&#8221; to its reference product but not an exact identical copy like a small-molecule generic.<sup>22<\/sup> This necessitates greater provider and patient education to build confidence in clinical equivalency. Furthermore, the FDA has a separate designation of &#8220;interchangeable biosimilar,&#8221; which allows for substitution at the pharmacy level without prescriber intervention, a higher standard that not all biosimilars meet.<sup>45<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Despite these complexities, the inpatient hospital setting represents one of the purest opportunities to realize savings from biosimilars. Inpatient reimbursement, often based on Diagnosis-Related Groups (DRGs), typically provides a single, bundled payment for a patient&#8217;s entire hospital stay, regardless of the specific drugs used.<sup>46<\/sup> This model is fundamentally different from the outpatient world, where complex rebate negotiations between manufacturers and Pharmacy Benefit Managers (PBMs) can create perverse financial incentives that discourage the use of lower-cost biosimilars.<sup>48<\/sup> In the inpatient setting, the financial incentive is direct and clear: since the hospital is not paid separately for the drug, any reduction in the drug&#8217;s acquisition cost flows directly to the institution&#8217;s bottom line, improving the margin on that patient&#8217;s admission.<sup>47<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Recent data shows that while inpatient biosimilar adoption is growing, there remains significant untapped potential.<sup>46<\/sup> With biosimilars offering an average wholesale acquisition cost (WAC) reduction of 35%\u2014and some as high as 55%\u2014a targeted inpatient biosimilar adoption program represents low-hanging fruit for many health systems.<sup>46<\/sup> The primary barriers are often internal (e.g., lack of provider education, slow formulary processes) rather than external (e.g., complex reimbursement schemes), making this a highly actionable cost-saving initiative for pharmacy leadership to champion.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>4.2 Case Studies in Action: Learning from the Real World<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Real-world examples illustrate the strategic nuances and potential pitfalls of navigating the patent cliff.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>The Trastuzumab (Herceptin) Case:<\/strong> This case study demonstrates how a brand manufacturer&#8217;s evergreening strategy can disrupt biosimilar uptake. Just before the patent on the original intravenous (IV) Herceptin expired, the manufacturer launched a new, patent-protected subcutaneous formulation. Even after IV biosimilars entered the market at a significant discount, the branded subcutaneous version retained a 20% market share in the Netherlands, reducing the total potential cost savings for the healthcare system.<sup>51<\/sup> This highlights the need for P&amp;T committees to critically evaluate the true clinical value and convenience of a new formulation against the substantial cost savings offered by a biosimilar of the original.<\/li>\n\n\n\n<li><strong>The Omeprazole\/Esomeprazole (Prilosec\/Nexium) Case:<\/strong> This is a classic example of a &#8220;chiral switch,&#8221; another common evergreening tactic. AstraZeneca used its patent thicket and an aggressive marketing campaign to transfer patient loyalty from its blockbuster drug Prilosec (omeprazole) to a new, patent-protected &#8220;me-too&#8221; drug, Nexium (esomeprazole), which offered no significant additional therapeutic value.<sup>17<\/sup> This strategy successfully blunted the financial impact of Prilosec&#8217;s patent expiration. It serves as a powerful cautionary tale for P&amp;T committees to remain vigilant and demand strong evidence of superior clinical outcomes before adding expensive, next-generation products to the formulary when a low-cost generic of the predecessor is imminent.<\/li>\n\n\n\n<li><strong>The Generic Transition Failure Case:<\/strong> A case involving a 91-year-old woman who was inadvertently taking both the brand and generic versions of two different medications (Flexeril\/cyclobenzaprine and Neurontin\/gabapentin) highlights a critical patient safety risk.<sup>52<\/sup> This error, which led to her hospitalization, underscores the absolute necessity of robust medication reconciliation processes and clear patient education during any transition from a brand to a generic drug. It demonstrates that the pharmacy&#8217;s responsibility extends beyond procurement and formulary placement to ensuring the safe and effective implementation of these changes at the patient level.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>4.3 Beyond the Spreadsheet: The Future of Pharmacy Budgeting<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The dynamic nature of the pharmaceutical market, with its unpredictable patent litigation outcomes and new drug launches, renders traditional, static annual budgeting processes inadequate.<sup>19<\/sup> To effectively manage this volatility, health systems must adopt more agile financial planning methodologies.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rolling Forecasts:<\/strong> The adoption of rolling forecasts, which are updated on a monthly or quarterly basis, is a crucial step. This approach allows the pharmacy budget to become a living, strategic tool. When new intelligence emerges\u2014such as a surprise settlement announcement that moves a generic launch date forward by six months\u2014the financial forecast can be immediately adjusted to reflect the new reality.<sup>19<\/sup> This provides leadership with a more accurate and timely view of financial performance and allows for proactive resource reallocation.<\/li>\n\n\n\n<li><strong>AI and Predictive Analytics:<\/strong> Looking ahead, artificial intelligence (AI) and predictive analytics hold the potential to revolutionize pharmaceutical expenditure forecasting.<sup>15<\/sup> AI algorithms can be trained on vast datasets of historical patent filings, litigation outcomes, market data, and clinical trial results to identify patterns and create more accurate, automated forecasts.<sup>55<\/sup> This can help identify overlooked cost-saving opportunities and model the potential impact of multiple future scenarios, moving the pharmacy from historical forecasting to true predictive financial modeling.<sup>57<\/sup><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Section 5: Overcoming Hurdles and Institutionalizing the Strategy<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Translating this strategic playbook into practice requires overcoming several common organizational and technical challenges.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>5.1 Addressing the Implementation Challenges<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Data Integration and Workflow Mismatch:<\/strong> A significant real-world hurdle is the difficulty of integrating complex, external patent data into existing hospital IT infrastructure like the EHR or pharmacy management systems.<sup>58<\/sup> Data can easily lose its clinical context, and if it is not presented to clinicians and managers within their natural workflows in a clear and concise format, it will not be used.<sup>58<\/sup> The solution lies not in trying to build a perfect, all-encompassing integration, but in creating simplified dashboards and focused reports that translate raw patent data into actionable clinical and financial recommendations for the P&amp;T committee and finance department.<\/li>\n\n\n\n<li><strong>Resource and Expertise Gaps:<\/strong> Most hospital pharmacies do not employ in-house patent attorneys. This expertise gap can be intimidating. A practical, tiered approach is recommended. A hospital can start by training an existing pharmacy analyst to leverage the free FDA resources. As the program demonstrates value, the hospital can build a business case for investing in a cost-effective commercial intelligence platform that automates much of the data gathering and analysis.<sup>39<\/sup> The goal is to build internal capacity for this high-value work.<\/li>\n\n\n\n<li><strong>The PBM Black Box:<\/strong> For hospitals that also manage a self-funded employee health plan or operate in the outpatient space, the opaque practices of PBMs can be a major barrier to realizing savings. Tactics like &#8220;spread pricing&#8221;\u2014where a PBM charges the health plan more for a generic drug than it reimburses the pharmacy\u2014can allow the intermediary to absorb the savings that should have gone to the plan and its members.<sup>48<\/sup> This reality reinforces the need for hospital leadership to demand radical transparency, pass-through pricing models, and robust audit rights in their PBM contracts to ensure that the financial benefits of generic and biosimilar conversion are fully captured.<sup>7<\/sup><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>5.2 A Call to Action: Recommendations for Hospital Leadership<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Institutionalizing this strategy requires commitment and action from leadership across the organization.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For the Chief Financial Officer (CFO):<\/strong> Champion the transition from static annual pharmacy budgets to dynamic, rolling forecasts. View investment in the necessary data tools and analyst resources not as a cost, but as a high-return-on-investment initiative that will yield millions in direct savings and provide far greater budget predictability.<sup>10<\/sup><\/li>\n\n\n\n<li><strong>For the Director of Pharmacy \/ Chief Pharmacy Officer (CPO):<\/strong> Lead the cultural shift within the pharmacy department by formally redefining its mission to include proactive financial stewardship. Establish the Pre-LOE review process as a standard operating procedure and assemble the cross-functional intelligence team to drive the work.<sup>34<\/sup><\/li>\n\n\n\n<li><strong>For the P&amp;T Committee Chair:<\/strong> Spearhead the evolution of the committee&#8217;s charter to formally recognize strategic cost management and value assessment as core functions alongside clinical efficacy and safety. Ensure that committee members receive the necessary training and resources to confidently evaluate pharmacoeconomic data and patent intelligence to inform their decisions.<sup>63<\/sup><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>5.3 Conclusion: The High-Performance Pharmacy of the Future<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Mastering the patent cliff is no longer a niche specialty for pharmaceutical manufacturers; it is a core competency for modern health system management. The relentless rise in drug costs is an existential threat to the financial stability of hospitals, and the predictable wave of patent expirations offers the most powerful and reliable lever to counteract this pressure. By moving from a reactive to a proactive posture\u2014by institutionalizing this intelligence-driven playbook\u2014hospitals can unlock hundreds of millions of dollars in savings across the system. This strategy mitigates budget volatility, reduces operational friction, and, most importantly, allows precious financial resources to be reinvested into the people, technology, and services that directly support the fundamental mission of providing the highest quality of patient care. The high-performance pharmacy of the future is not just a dispenser of medications; it is a strategic financial asset to the entire health system.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Works cited<\/strong><\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Patent cliff &#8211; Wikipedia, accessed August 7, 2025, <a href=\"https:\/\/en.wikipedia.org\/wiki\/Patent_cliff\">https:\/\/en.wikipedia.org\/wiki\/Patent_cliff<\/a><\/li>\n\n\n\n<li>Patent Cliff: What It Means, How It Works &#8211; Investopedia, accessed August 7, 2025, <a href=\"https:\/\/www.investopedia.com\/terms\/p\/patent-cliff.asp\">https:\/\/www.investopedia.com\/terms\/p\/patent-cliff.asp<\/a><\/li>\n\n\n\n<li>The Multi-Billion Dollar Countdown: Decoding the Patent Cliff and Seizing the Generic Opportunity &#8211; DrugPatentWatch, accessed August 7, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/patent-expirations-seizing-opportunities-in-the-generic-drug-market\/\">https:\/\/www.drugpatentwatch.com\/blog\/patent-expirations-seizing-opportunities-in-the-generic-drug-market\/<\/a><\/li>\n\n\n\n<li>Navigating pharma loss of exclusivity | EY &#8211; US, accessed August 7, 2025, <a href=\"https:\/\/www.ey.com\/en_us\/insights\/life-sciences\/navigating-pharma-loss-of-exclusivity\">https:\/\/www.ey.com\/en_us\/insights\/life-sciences\/navigating-pharma-loss-of-exclusivity<\/a><\/li>\n\n\n\n<li>Rising Drug Costs Are Handcuffing Healthcare &#8211; The New Jersey &#8230;, accessed August 7, 2025, <a href=\"https:\/\/www.njha.com\/media\/548875\/CHART-Bulletin-Drug-Costs.pdf\">https:\/\/www.njha.com\/media\/548875\/CHART-Bulletin-Drug-Costs.pdf<\/a><\/li>\n\n\n\n<li>Prescription Drugs: Spending, Use, and Prices | Congressional Budget Office, accessed August 7, 2025, <a href=\"https:\/\/www.cbo.gov\/publication\/57772\">https:\/\/www.cbo.gov\/publication\/57772<\/a><\/li>\n\n\n\n<li>The Patent Cliff Playbook: A Strategic Guide to Formulary &#8230;, accessed August 7, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/the-patent-cliff-playbook-a-strategic-guide-to-formulary-management-in-the-age-of-generic-entry\/\">https:\/\/www.drugpatentwatch.com\/blog\/the-patent-cliff-playbook-a-strategic-guide-to-formulary-management-in-the-age-of-generic-entry\/<\/a><\/li>\n\n\n\n<li>Formulary Management | AMCP.org, accessed August 7, 2025, <a href=\"https:\/\/www.amcp.org\/concepts-managed-care-pharmacy\/formulary-management\">https:\/\/www.amcp.org\/concepts-managed-care-pharmacy\/formulary-management<\/a><\/li>\n\n\n\n<li>The Complete Guide to Formulary Management in Hospital Pharmacies &#8211; MedReb8, accessed August 7, 2025, <a href=\"https:\/\/www.medreb8.com\/blog\/the-complete-guide-to-formulary-management-in-hospital-pharmacies\">https:\/\/www.medreb8.com\/blog\/the-complete-guide-to-formulary-management-in-hospital-pharmacies<\/a><\/li>\n\n\n\n<li>The Health Care Budget Process &#8211; ASHP Publications, accessed August 7, 2025, <a href=\"https:\/\/publications.ashp.org\/previewpdf\/book\/9781585283187\/ch003.xml?pdfJsInlineViewToken=449986171&amp;inlineView=true\">https:\/\/publications.ashp.org\/previewpdf\/book\/9781585283187\/ch003.xml?pdfJsInlineViewToken=449986171&amp;inlineView=true<\/a><\/li>\n\n\n\n<li>Drug Patent Life: The Complete Guide to Pharmaceutical Patent &#8230;, accessed August 7, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/how-long-do-drug-patents-last\/\">https:\/\/www.drugpatentwatch.com\/blog\/how-long-do-drug-patents-last\/<\/a><\/li>\n\n\n\n<li>How Drug Life-Cycle Management Patent Strategies May Impact Formulary Management, accessed August 7, 2025, <a href=\"https:\/\/www.ajmc.com\/view\/a636-article\">https:\/\/www.ajmc.com\/view\/a636-article<\/a><\/li>\n\n\n\n<li>The Tipping Point: Navigating the Financial and Strategic Impact of &#8230;, accessed August 7, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/the-impact-of-patent-expiry-on-drug-prices-a-systematic-literature-review\/\">https:\/\/www.drugpatentwatch.com\/blog\/the-impact-of-patent-expiry-on-drug-prices-a-systematic-literature-review\/<\/a><\/li>\n\n\n\n<li>Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry &#8211; PMC, accessed August 7, 2025, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4899342\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4899342\/<\/a><\/li>\n\n\n\n<li>A Quick Guide to Pharmaceutical Patents and Their Types &#8211; PatSeer, accessed August 7, 2025, <a href=\"https:\/\/patseer.com\/a-quick-guide-to-pharmaceutical-patents-and-their-types\/\">https:\/\/patseer.com\/a-quick-guide-to-pharmaceutical-patents-and-their-types\/<\/a><\/li>\n\n\n\n<li>Optimizing Your Drug Patent Strategy: A Comprehensive Guide for Pharmaceutical Companies &#8211; DrugPatentWatch, accessed August 7, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/optimizing-your-drug-patent-strategy-a-comprehensive-guide-for-pharmaceutical-companies\/\">https:\/\/www.drugpatentwatch.com\/blog\/optimizing-your-drug-patent-strategy-a-comprehensive-guide-for-pharmaceutical-companies\/<\/a><\/li>\n\n\n\n<li>A case study of AstraZeneca&#8217;s omeprazole\/esomeprazole chiral switch strategy &#8211; GaBIJ, accessed August 7, 2025, <a href=\"https:\/\/gabi-journal.net\/a-case-study-of-astrazenecas-omeprazole-esomeprazole-chiral-switch-strategy.html\">https:\/\/gabi-journal.net\/a-case-study-of-astrazenecas-omeprazole-esomeprazole-chiral-switch-strategy.html<\/a><\/li>\n\n\n\n<li>How to own a Market you Don&#8217;t Own: Market Access Strategies Post-Patent Expiration, accessed August 7, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/how-to-own-a-market-you-dont-own-market-access-strategies-post-patent-expiration\/\">https:\/\/www.drugpatentwatch.com\/blog\/how-to-own-a-market-you-dont-own-market-access-strategies-post-patent-expiration\/<\/a><\/li>\n\n\n\n<li>Healthcare Financial Planning, Budgeting, and Forecasting in 2025, accessed August 7, 2025, <a href=\"https:\/\/www.golimelight.com\/blog\/healthcare-financial-planning-budgeting-and-forecasting\">https:\/\/www.golimelight.com\/blog\/healthcare-financial-planning-budgeting-and-forecasting<\/a><\/li>\n\n\n\n<li>Healthcare and Hospital Budgeting: A Complete Guide | Syntellis, accessed August 7, 2025, <a href=\"https:\/\/www.stratadecision.com\/guide-to-healthcare-and-hospital-budgeting\">https:\/\/www.stratadecision.com\/guide-to-healthcare-and-hospital-budgeting<\/a><\/li>\n\n\n\n<li>Pharmaceutical Patent Regulation in the United States &#8211; The Actuary &#8230;, accessed August 7, 2025, <a href=\"https:\/\/www.theactuarymagazine.org\/pharmaceutical-patent-regulation-in-the-united-states\/\">https:\/\/www.theactuarymagazine.org\/pharmaceutical-patent-regulation-in-the-united-states\/<\/a><\/li>\n\n\n\n<li>Biosimilar Market Trends &#8211; Strategic Services Group Blog &#8230;, accessed August 7, 2025, <a href=\"https:\/\/www.ssgmi.com\/resources\/blog\/biosimilar-market-trends_ae1498.html\">https:\/\/www.ssgmi.com\/resources\/blog\/biosimilar-market-trends_ae1498.html<\/a><\/li>\n\n\n\n<li>GENERIC DRUGS IN THE UNITED STATES: POLICIES TO ADDRESS PRICING AND COMPETITION, accessed August 7, 2025, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6355356\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6355356\/<\/a><\/li>\n\n\n\n<li>The Persistent Problem: Why Hospitals Keep Running Out of Generic Drugs, accessed August 7, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/the-persistent-problem-why-hospitals-keep-running-out-of-generic-drugs\/\">https:\/\/www.drugpatentwatch.com\/blog\/the-persistent-problem-why-hospitals-keep-running-out-of-generic-drugs\/<\/a><\/li>\n\n\n\n<li>Drug Competition Series \u2013 Analysis of New Generic &#8230; &#8211; HHS ASPE, accessed August 7, 2025, <a href=\"https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/510e964dc7b7f00763a7f8a1dbc5ae7b\/aspe-ib-generic-drugs-competition.pdf\">https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/510e964dc7b7f00763a7f8a1dbc5ae7b\/aspe-ib-generic-drugs-competition.pdf<\/a><\/li>\n\n\n\n<li>New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices &#8211; FDA, accessed August 7, 2025, <a href=\"https:\/\/www.fda.gov\/media\/133509\/download\">https:\/\/www.fda.gov\/media\/133509\/download<\/a><\/li>\n\n\n\n<li>Pharmacy and Therapeutics &#8211; Wikipedia, accessed August 7, 2025, <a href=\"https:\/\/en.wikipedia.org\/wiki\/Pharmacy_and_Therapeutics\">https:\/\/en.wikipedia.org\/wiki\/Pharmacy_and_Therapeutics<\/a><\/li>\n\n\n\n<li>Pharmacy and Therapeutics Committee &#8211; Basicmedical Key, accessed August 7, 2025, <a href=\"https:\/\/basicmedicalkey.com\/pharmacy-and-therapeutics-committee\/\">https:\/\/basicmedicalkey.com\/pharmacy-and-therapeutics-committee\/<\/a><\/li>\n\n\n\n<li>Best Practices for Pharmacy &amp; Therapeutics (P&amp;T &#8230; &#8211; National Forum, accessed August 7, 2025, <a href=\"https:\/\/www.nationalforum.org\/wp-content\/uploads\/2019\/11\/PT-Committee-Best-Practices-Checklist-11.13.19.pdf\">https:\/\/www.nationalforum.org\/wp-content\/uploads\/2019\/11\/PT-Committee-Best-Practices-Checklist-11.13.19.pdf<\/a><\/li>\n\n\n\n<li>Medical cost trend: Behind the numbers &#8211; PwC, accessed August 7, 2025, <a href=\"https:\/\/www.pwc.com\/us\/en\/industries\/health-industries\/library\/behind-the-numbers.html\">https:\/\/www.pwc.com\/us\/en\/industries\/health-industries\/library\/behind-the-numbers.html<\/a><\/li>\n\n\n\n<li>A primer on formulary structures and strategies &#8211; PMC, accessed August 7, 2025, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10838136\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10838136\/<\/a><\/li>\n\n\n\n<li>The Changing Roles of P&amp;T Committees: A Look Back at the Last Decade and a Look Forward to 2020 &#8211; PMC &#8211; PubMed Central, accessed August 7, 2025, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4218672\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4218672\/<\/a><\/li>\n\n\n\n<li>Formulary Evaluation Using a Class Review Approach: Experience and Results From an Academic Medical Center &#8211; PubMed Central, accessed August 7, 2025, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3684187\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3684187\/<\/a><\/li>\n\n\n\n<li>Medication Cost Management Strategies for Hospitals and &#8230; &#8211; ASHP, accessed August 7, 2025, <a href=\"https:\/\/www.ashp.org\/-\/media\/assets\/policy-guidelines\/docs\/guidelines\/medication-cost-management-strategies-hospitals-health-systems.pdf\">https:\/\/www.ashp.org\/-\/media\/assets\/policy-guidelines\/docs\/guidelines\/medication-cost-management-strategies-hospitals-health-systems.pdf<\/a><\/li>\n\n\n\n<li>Approved Drug Products with Therapeutic Equivalence Evaluations &#8230;, accessed August 7, 2025, <a href=\"https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book\">https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book<\/a><\/li>\n\n\n\n<li>Freshly Squeezed: Orange Book History and Key Updates at 45, accessed August 7, 2025, <a href=\"https:\/\/www.fdli.org\/2025\/05\/freshly-squeezed-orange-book-history-and-key-updates-at-45\/\">https:\/\/www.fdli.org\/2025\/05\/freshly-squeezed-orange-book-history-and-key-updates-at-45\/<\/a><\/li>\n\n\n\n<li>FDA Purple Book, accessed August 7, 2025, <a href=\"https:\/\/purplebooksearch.fda.gov\/\">https:\/\/purplebooksearch.fda.gov\/<\/a><\/li>\n\n\n\n<li>About the Purple Book, accessed August 7, 2025, <a href=\"https:\/\/purplebooksearch.fda.gov\/about\">https:\/\/purplebooksearch.fda.gov\/about<\/a><\/li>\n\n\n\n<li>DrugPatentWatch | Software Reviews &amp; Alternatives &#8211; Crozdesk, accessed August 7, 2025, <a href=\"https:\/\/crozdesk.com\/software\/drugpatentwatch\">https:\/\/crozdesk.com\/software\/drugpatentwatch<\/a><\/li>\n\n\n\n<li>DrugPatentWatch&#8217;s rapid research capabilities have elevated our &#8230;, accessed August 7, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/\">https:\/\/www.drugpatentwatch.com\/<\/a><\/li>\n\n\n\n<li>Maximizing Value in the Pharmacy Revenue Cycle &#8211; YouTube, accessed August 7, 2025, <a href=\"https:\/\/www.youtube.com\/watch?v=UhJnLOiPXrE\">https:\/\/www.youtube.com\/watch?v=UhJnLOiPXrE<\/a><\/li>\n\n\n\n<li>PHARMACY AND THERAPEUTICS (P&amp;T) COMMITTEE MEETING MAY 15, 2019 &#8211; NC State Health Plan, accessed August 7, 2025, <a href=\"https:\/\/www.shpnc.gov\/documents\/pharmacy-and-therapeutics\/pt-booklet-may-2019-secured\/download\">https:\/\/www.shpnc.gov\/documents\/pharmacy-and-therapeutics\/pt-booklet-may-2019-secured\/download<\/a><\/li>\n\n\n\n<li>Pharmacy and Therapeutics Committee Policies and Procedures &#8211; HealthPartners, accessed August 7, 2025, <a href=\"https:\/\/www.healthpartners.com\/ucm\/groups\/public\/@hp\/@public\/documents\/documents\/cntrb_043361.pdf\">https:\/\/www.healthpartners.com\/ucm\/groups\/public\/@hp\/@public\/documents\/documents\/cntrb_043361.pdf<\/a><\/li>\n\n\n\n<li>ASHP Guidelines: Minimum Standard for Pharmacies in Hospitals, accessed August 7, 2025, <a href=\"https:\/\/www.ashpmedia.org\/softchalk\/softchalkleadsurveyorresourcelink\/3%20SettingsGdlMinHosp.pdf\">https:\/\/www.ashpmedia.org\/softchalk\/softchalkleadsurveyorresourcelink\/3%20SettingsGdlMinHosp.pdf<\/a><\/li>\n\n\n\n<li>An Overview of Biosimilar Regulatory Approvals by the EMA and FDA &#8211; DrugPatentWatch, accessed August 7, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/the-biosimilar-landscape-an-overview-of-regulatory-approvals-by-the-ema-and-fda\/\">https:\/\/www.drugpatentwatch.com\/blog\/the-biosimilar-landscape-an-overview-of-regulatory-approvals-by-the-ema-and-fda\/<\/a><\/li>\n\n\n\n<li>Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems, accessed August 7, 2025, <a href=\"https:\/\/www.pharmacytimes.com\/view\/inpatient-biosimilar-use-grows-offering-cost-saving-opportunities-for-health-systems\">https:\/\/www.pharmacytimes.com\/view\/inpatient-biosimilar-use-grows-offering-cost-saving-opportunities-for-health-systems<\/a><\/li>\n\n\n\n<li>Hospital Impact\u2014Reimbursement models a roadblock to biosimilar adoption, accessed August 7, 2025, <a href=\"https:\/\/www.fiercehealthcare.com\/hospitals\/hospital-impact-reimbursement-models-a-roadblock-to-biosimilar-adoption\">https:\/\/www.fiercehealthcare.com\/hospitals\/hospital-impact-reimbursement-models-a-roadblock-to-biosimilar-adoption<\/a><\/li>\n\n\n\n<li>FTC Releases Interim Staff Report on Prescription Drug Middlemen, accessed August 7, 2025, <a href=\"https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2024\/07\/ftc-releases-interim-staff-report-prescription-drug-middlemen\">https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2024\/07\/ftc-releases-interim-staff-report-prescription-drug-middlemen<\/a><\/li>\n\n\n\n<li>PBMs, Formularies, and Rebates: What Investors Should Know &#8211; DrugPatentWatch, accessed August 7, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/pbms-formularies-and-rebates-what-investors-should-know\/\">https:\/\/www.drugpatentwatch.com\/blog\/pbms-formularies-and-rebates-what-investors-should-know\/<\/a><\/li>\n\n\n\n<li>Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems, accessed August 7, 2025, <a href=\"https:\/\/www.centerforbiosimilars.com\/view\/inpatient-biosimilar-use-grows-offering-cost-saving-opportunities-for-health-systems\">https:\/\/www.centerforbiosimilars.com\/view\/inpatient-biosimilar-use-grows-offering-cost-saving-opportunities-for-health-systems<\/a><\/li>\n\n\n\n<li>The impact of an &#8216;evergreening&#8217; strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands &#8211; Bohrium, accessed August 7, 2025, <a href=\"https:\/\/www.bohrium.com\/paper-details\/the-impact-of-an-evergreening-strategy-nearing-patent-expiration-on-the-uptake-of-biosimilars-and-public-healthcare-costs-a-case-study-on-the-introduction-of-a-second-administration-form-of-trastuzumab-in-the-netherlands\/951457466955071496-11580\">https:\/\/www.bohrium.com\/paper-details\/the-impact-of-an-evergreening-strategy-nearing-patent-expiration-on-the-uptake-of-biosimilars-and-public-healthcare-costs-a-case-study-on-the-introduction-of-a-second-administration-form-of-trastuzumab-in-the-netherlands\/951457466955071496-11580<\/a><\/li>\n\n\n\n<li>Medication Reconciliation Victory After an Avoidable Error | PSNet &#8211; AHRQ, accessed August 7, 2025, <a href=\"https:\/\/psnet.ahrq.gov\/web-mm\/medication-reconciliation-victory-after-avoidable-error\">https:\/\/psnet.ahrq.gov\/web-mm\/medication-reconciliation-victory-after-avoidable-error<\/a><\/li>\n\n\n\n<li>Projections of Public Spending on Pharmaceuticals: A Review of Methods &#8211; PMC, accessed August 7, 2025, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11929675\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11929675\/<\/a><\/li>\n\n\n\n<li>Breakthroughs or bottlenecks? Pharma industry outlook, trends and strategies for 2025 &#8211; ZS, accessed August 7, 2025, <a href=\"https:\/\/www.zs.com\/insights\/pharmaceutical-trends-2025-outlook-ai-supplychain-and-beyond\">https:\/\/www.zs.com\/insights\/pharmaceutical-trends-2025-outlook-ai-supplychain-and-beyond<\/a><\/li>\n\n\n\n<li>Assessment of Automation Models in Hospital Pharmacy: Systematic Review of Technologies, Practices, and Clinical Impacts &#8211; PubMed Central, accessed August 7, 2025, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11869230\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11869230\/<\/a><\/li>\n\n\n\n<li>Patentability challenges associated with emerging pharmaceutical technologies, accessed August 7, 2025, <a href=\"https:\/\/www.researchgate.net\/publication\/353223080_Patentability_challenges_associated_with_emerging_pharmaceutical_technologies\">https:\/\/www.researchgate.net\/publication\/353223080_Patentability_challenges_associated_with_emerging_pharmaceutical_technologies<\/a><\/li>\n\n\n\n<li>Next in pharma 2025: The future is now &#8211; PwC, accessed August 7, 2025, <a href=\"https:\/\/www.pwc.com\/us\/en\/industries\/pharma-life-sciences\/pharmaceutical-industry-trends.html\">https:\/\/www.pwc.com\/us\/en\/industries\/pharma-life-sciences\/pharmaceutical-industry-trends.html<\/a><\/li>\n\n\n\n<li>Data Integration Challenges in Healthcare &#8211; PatientCalls.com, accessed August 7, 2025, <a href=\"https:\/\/www.patientcalls.com\/blog\/data-integration-challenges-in-healthcare\/\">https:\/\/www.patientcalls.com\/blog\/data-integration-challenges-in-healthcare\/<\/a><\/li>\n\n\n\n<li>US20090132586A1 &#8211; Management of Medical Workflow &#8211; Google Patents, accessed August 7, 2025, <a href=\"https:\/\/patents.google.com\/patent\/US20090132586A1\/en\">https:\/\/patents.google.com\/patent\/US20090132586A1\/en<\/a><\/li>\n\n\n\n<li>Art and Challenges of Precision Medicine: Interpreting and Integrating Genomic Data Into Clinical Practice &#8211; ASCO Publications, accessed August 7, 2025, <a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_200759\">https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_200759<\/a><\/li>\n\n\n\n<li>U.S. Consumers Overpay for Generic Drugs &#8211; May 31, 2022 &#8211; USC Schaeffer, accessed August 7, 2025, <a href=\"https:\/\/schaeffer.usc.edu\/research\/u-s-consumers-overpay-for-generic-drugs\/\">https:\/\/schaeffer.usc.edu\/research\/u-s-consumers-overpay-for-generic-drugs\/<\/a><\/li>\n\n\n\n<li>Improve pharmacy budgeting by following these successful tips, accessed August 7, 2025, <a href=\"https:\/\/www.clinician.com\/ext\/resources\/pdfs\/articles\/97\/972\/9728\/97289\/972898.pdf\">https:\/\/www.clinician.com\/ext\/resources\/pdfs\/articles\/97\/972\/9728\/97289\/972898.pdf<\/a><\/li>\n\n\n\n<li>Evaluating the Training, Responsibilities, and Practices of P&amp;T &#8230;, accessed August 7, 2025, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10398261\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10398261\/<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Introduction: The Strategic Imperative of the Patent Cliff for Health Systems The term &#8220;patent cliff&#8221; signifies a period of immense [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":35739,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-34444","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=34444"}],"version-history":[{"count":2,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34444\/revisions"}],"predecessor-version":[{"id":35740,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34444\/revisions\/35740"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/35739"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=34444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=34444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=34444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}